{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T01:46:23Z","timestamp":1780364783247,"version":"3.54.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"3-4","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.ando.2020.03.009","type":"journal-article","created":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T07:35:34Z","timestamp":1590564934000},"page":"179-181","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Aldosterone receptor antagonists"],"prefix":"10.1016","volume":"82","author":[{"given":"Michel","family":"Azizi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ando.2020.03.009_bib0130","doi-asserted-by":"crossref","first-page":"T125","DOI":"10.1530\/JOE-16-0600","article-title":"30 years of the mineralocorticoid receptor: mineralocorticoid receptor antagonists: 60 years of research and development","volume":"234","author":"Kolkhof","year":"2017","journal-title":"J Endocrinol"},{"key":"10.1016\/j.ando.2020.03.009_bib0135","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.mce.2008.10.029","article-title":"Aldosterone and mineralocorticoid receptors: clinical studies and basic biology","volume":"301","author":"Funder","year":"2009","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.ando.2020.03.009_bib0140","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/01.mnh.0000165889.60254.98","article-title":"Aldosterone and end-organ damage","volume":"14","author":"Brown","year":"2005","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.ando.2020.03.009_bib0145","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1001\/archinte.168.11.1159","article-title":"Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion","volume":"168","author":"Gaddam","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ando.2020.03.009_bib0150","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (pathway-2): A randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ando.2020.03.009_bib0155","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 esc\/esh guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ando.2020.03.009_bib0160","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","article-title":"Resistant hypertension: Detection, evaluation, and management: A scientific statement from the american heart association","volume":"72","author":"Carey","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.ando.2020.03.009_bib0165","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S0140-6736(18)31808-7","article-title":"Heart failure drug treatment","volume":"393","author":"Rossignol","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ando.2020.03.009_bib0170","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/HJH.0b013e32832810ed","article-title":"Aldosterone-receptor antagonism in hypertension","volume":"27","author":"Jansen","year":"2009","journal-title":"J Hypertens"},{"key":"10.1016\/j.ando.2020.03.009_bib0175","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.mce.2003.10.008","article-title":"The 45-year story of the development of an anti-aldosterone more specific than spironolactone","volume":"217","author":"Menard","year":"2004","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.ando.2020.03.009_bib0180","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/HJH.0b013e3283455ca5","article-title":"A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism","volume":"29","author":"Parthasarathy","year":"2011","journal-title":"J Hypertens"},{"key":"10.1016\/j.ando.2020.03.009_bib0185","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/ajh\/hpu151","article-title":"Systematic review and meta-analysis of the prevalence of resistant hypertension in treated hypertensive populations","volume":"28","author":"Achelrod","year":"2015","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.ando.2020.03.009_bib0190","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1097\/00004872-200111000-00018","article-title":"High prevalence of cardiac and extracardiac target organ damage in refractory hypertension","volume":"19","author":"Cuspidi","year":"2001","journal-title":"J Hypertens"},{"key":"10.1016\/j.ando.2020.03.009_bib0195","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/hr.2013.30","article-title":"Resistant hypertension and target organ damage","volume":"36","author":"Muiesan","year":"2013","journal-title":"Hypertens Res"},{"key":"10.1016\/j.ando.2020.03.009_bib0200","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1161\/CIRCULATIONAHA.111.068064","article-title":"Incidence and prognosis of resistant hypertension in hypertensive patients","volume":"125","author":"Daugherty","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ando.2020.03.009_bib0205","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1161\/HYPERTENSIONAHA.108.189141","article-title":"Resistant hypertension: Diagnosis, evaluation, and treatment. A scientific statement from the american heart association professional education committee of the council for high blood pressure research","volume":"51","author":"Calhoun","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.ando.2020.03.009_bib0210","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1001\/jama.2014.5180","article-title":"Resistant hypertension: a review of diagnosis and management","volume":"311","author":"Vongpatanasin","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.ando.2020.03.009_bib0215","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/jch.12472","article-title":"The role of continuous positive airway pressure in blood pressure control for patients with obstructive sleep apnea and hypertension: a meta-analysis of randomized controlled trials","volume":"17","author":"Hu","year":"2015","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.ando.2020.03.009_bib0220","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev-med-042711-135929","article-title":"Hyperaldosteronism as a common cause of resistant hypertension","volume":"64","author":"Calhoun","year":"2013","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.ando.2020.03.009_bib0225","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.amjmed.2016.01.039","article-title":"Resistant hypertension and the pivotal role for mineralocorticoid receptor antagonists: a clinical update","volume":"129","author":"Epstein","year":"2016","journal-title":"Am J Med"},{"key":"10.1016\/j.ando.2020.03.009_bib0230","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1093\/ajh\/hpv031","article-title":"The effects of aldosterone antagonists in patients with resistant hypertension: a meta-analysis of randomized and nonrandomized studies","volume":"28","author":"Dahal","year":"2015","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.ando.2020.03.009_bib0235","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S2213-8587(18)30071-8","article-title":"Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: The pathway-2 mechanisms substudies","volume":"6","author":"Williams","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ando.2020.03.009_bib0240","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1161\/HYPERTENSIONAHA.117.10662","article-title":"Spironolactone versus clonidine as a fourth-drug therapy for resistant hypertension: The rehot randomized study (resistant hypertension optimal treatment)","volume":"71","author":"Krieger","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.ando.2020.03.009_bib0245","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist bay 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: A randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ando.2020.03.009_bib0250","doi-asserted-by":"crossref","first-page":"h4762","DOI":"10.1136\/bmj.h4762","article-title":"Investigating hyperkalaemia in adults","volume":"351","author":"McDonald","year":"2015","journal-title":"BMJ"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426620300445?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426620300445?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T22:53:30Z","timestamp":1757717610000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003426620300445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":25,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0003426620300445"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2020.03.009","relation":{},"ISSN":["0003-4266"],"issn-type":[{"value":"0003-4266","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aldosterone receptor antagonists","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2020.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}